Vol 10, No 1 (2021)
Research paper
Published online: 2020-11-27

open access

Page views 787
Article views/downloads 699
Get Citation

Connect on Social Media

Connect on Social Media

Serum magnesium and visfatin levels in newly diagnosed non-obese type 2 diabetes without insulin resistance: a cross-sectional study

Shatha R. ‎Moustafa ‎1, Iman M. Jebur2, ‎Muntadher A. Hasan2, Marwan S.M. Al-Nimer1
Clin Diabetol 2021;10(1):123-128.


Background. Previous studies demonstrated that type 2 diabetes (T2D) patients have low serum magnesium and high serum levels of visfatin. This study aimed to show the relationship between serum levels of insulin, visfatin, and magnesium in T2D patients characterized by a non-insulin resistance status.
Methods. This was a cross-sectional study conducted in the Hawler Medical University, Kurdistan Region, Iraq from April 2019 to March 2020. A total number of 130 T2D patients and 45 healthy subjects were enrolled in the study. T2D patients with scores of homeostasis model assessment — insulin resistance (HOMA-IR) of < 2.5 were included. Serum levels of magnesium, visfatin, and glycemic indices, including fasting serum glucose, insulin, visfatin, and glycated hemoglobin were determined.
Results. The serum level of visfatin is significantly higher in T2D patients than the corresponding values of the healthy subjects. Serum magnesium level is significantly correlated with the percentage of the glycated hemoglobin (Spearman’s correlation factor = 0.184, P = 0.036), and a positive significant correlation between serum insulin and visfatin (r = 0.216, P = 0.014) was observed. Multivariate regression analysis of the association of fasting serum insulin as a dependent variable with serum magnesium and visfatin as independent variables showed a non-significant positive correlation (r = 0.197, P = 0.082).
Conclusion. Significant low serum levels of magnesium and visfatin are observed in non-insulin resistant T2D patients with a HOMA-IR score of < 2.5. Serum visfatin and magnesium levels showed significant correlations with glycemic indices.

Article available in PDF format

View PDF Download PDF file


  1. Gommers LMM, Hoenderop JGJ, Bindels RJM, et al. Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? Diabetes. 2016; 65(1): 3–13.
  2. Kumari B, Yadav UCS. Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements. Curr Mol Med. 2018; 18(2): 116–125.
  3. Mooren FC. Magnesium and disturbances in carbohydrate metabolism. Diabetes Obes Metab. 2015; 17(9): 813–823.
  4. Takaya J, Yamato F, Kaneko K, et al. Intracellular magnesium and insulin resistance. Magnes Res. 2004; 17(2): 126–136.
  5. Zhang Y, Li Q, Xin Yi, et al. Association between serum magnesium and common complications of diabetes mellitus. Technol Health Care. 2018; 26(S1): 379–387.
  6. Zhang Qi, Ji L, Zheng H, et al. Low serum phosphate and magnesium levels are associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018; 146: 1–7.
  7. Verma H, Garg R. Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: a systematic review and meta-analysis. J Hum Nutr Diet. 2017; 30(5): 621–633.
  8. Veronese N, Watutantrige-Fernando S, Luchini C, et al. Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials. Eur J Clin Nutr. 2016; 70(12): 1354–1359.
  9. Radzicka S, Pietryga M, Iciek R, et al. The role of visfatin in pathogenesis of gestational diabetes (GDM). Ginekol Pol. 2018; 89(9): 518–521.
  10. Legakis I, Mantzouridis T, Bouboulis G, et al. Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab. 2016; 60(1): 76–78.
  11. Hetta HF, Ez-Eldeen ME, Mohamed GA, et al. Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance. Egypt J Immunol. 2018; 25(2): 141–151.
  12. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 42(Suppl 1): S13–S28.
  13. Singh Y, Garg MK, Tandon N, et al. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013; 5(4): 245–251.
  14. Mihai G, Gasparik AI, Pascanu IM, et al. The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis. Aging Clin Exp Res. 2019; 31(6): 889–895.
  15. Heo YuJ, Choi SE, Jeon JaY, et al. Visfatin Induces Inflammation and Insulin Resistance via the NF-B and STAT3 Signaling Pathways in Hepatocytes. J Diabetes Res. 2019; 2019: 4021623.
  16. Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 2006; 49(8): 1909–1914.
  17. Bala M, Martin J, Kopp A, et al. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1). J Clin Endocrinol Metab. 2011; 96(8): 2493–2501.
  18. Noor MM, Nazir Q, Khan TM, et al. Association Between Low Serum Magnesium Level And Type 2 Diabetes Mellitus In Abbottabad. J Ayub Med Coll Abbottabad. 2019; 31(2): 226–229.
  19. Simental-Mendía LE, Sahebkar A, Rodríguez-Morán M, et al. A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacol Res. 2016; 111: 272–282.
  20. Soyoral YU, Erkoc R, Begenik H, et al. Relationship between visfatin and some clinical and biochemical parametres in peritoneal dialysis patients. J Pak Med Assoc. 2012; 62(11): 1179–1183.
  21. Kieboom BCT, Ligthart S, Dehghan A, et al. Serum magnesium and the risk of prediabetes: a population-based cohort study. Diabetologia. 2017; 60(5): 843–853.